Rationale: Angiotensin (Ang) II exerts diverse physiological actions in both the peripheral and central neural systems. It was reported that the activity of Ang II is higher in the nucleus tractus solitarii (NTS) of spontaneously hypertensive rats (SHRs) and that angiotensin type-1 receptors are colocalized with NAD(P)H oxidase in the neurons of the NTS, resulting in the induction of local reactive oxygen species production by Ang II. However, the signaling mechanisms of Ang II that induce hypertension remain unclear. Objective: The aim of this study was to investigate the possible signaling pathways involved in Ang II-mediated blood pressure regulation in the NTS. Methods and Results: Male SHRs were treated with losartan or tempol for 2 weeks, after which systolic blood pressure was observed to decrease significantly. Dihydroethidium staining showed many cells with high reactive oxygen species in the NTS of SHRs. The addition of losartan or tempol decreased the numbers of reactive oxygen species-positive cells in the NTS. The systemic administration of losartan or tempol reduced the systolic blood pressure and increased NO production. Immunoblotting and immunohistochemical analysis further showed that inhibition of Ang II activity by losartan or tempol significantly increased the expression extracellular signal-regulated kinase (ERK)1/2, ribosomal protein S6 kinase (RSK), and also increased neuronal NO synthase (nNOS) phosphorylation. RSK was also found to bind directly to nNOS and induce phosphorylation at the Ser1416 position. Conclusions: Taken together, these results suggest that the ERK1/2-RSK-nNOS signaling pathway may play a significant role in Ang II-mediated central blood pressure regulation. (Circ Res. 2010;106:788-795.)
T he nucleus tractus solitarii (NTS), which is located in the dorsal medulla of the brain stem, is the primary site of termination of the vagus and glossopharyngeal nerves. The NTS participates in cardiovascular, gastric, and gustatory control. Our previous studies demonstrated that several neuromodulators are involved in cardiovascular control of the NTS, including ATP, 1 adenosine, 2 neuropeptide Y, 3 angiotensin (Ang) II, 4 NO, 5 carbon monoxide, 6 and insulin. 7 Ang II is a powerful vasoconstrictor in the peripheral blood system that exerts effects on the central nervous system, regulating fluid balance and the secretion of aldosterone. Hyperactivity of Ang II has been shown to play a major role in hypertension. 8, 9 Ang II is produced from enzymatic cleavage of angiotensinogen by renin and then by angiotensin converting enzyme. These pathological and physiological actions of Ang II are mediated through its type 1 receptor (AT 1 R). 10 Recent evidence suggests that hyperactivity of the brain renin-angiotensin system may play a critical role in mediating hypertension in spontaneously hypertensive rats (SHRs). 11 Significant differences in AT 1 R density were seen in the NTS of SHRs and Wistar-Kyoto (WKY) rats, as SHRs had higher expression levels than WKY rats. 11 The term "oxidative stress" describes chronically elevated levels of reactive oxygen species (ROS) and is associated with cardiovascular disease. 12 ROS play a role in central autonomic networks that are involved in Ang II-mediated signaling. 13 NAD(P)H oxidase is the main source of Ang II-induced ROS in neurons. 14 NAD(P)H oxidase is composed of 2 catalytic subunits (gp91 phox and p22 phox ) and 4 regulatory subunits (p47 phox , p40 phox , p67 phox , and Rac1). Importantly, gp91 phox and AT 1 R are colocalized in the neurons of the NTS, facilitating local ROS production by Ang II. 15 NO is synthesized by the enzyme NO synthase. There are 3 different types of NO synthases: neuronal NO synthase (nNOS), endothelial NO synthase (eNOS), and inducible NO synthase (iNOS). 16 In vivo eNOS gene transfer experiments in the NTS caused hypotension and bradycardia. [17] [18] [19] Our previous studies demonstrated that, when microinjected into the NTS, a nonselective inhibitor of NO synthase, increased arterial pressure and renal sympathetic nerve activity. 5 A recent study also reported that selective inhibition of nNOS in the brain increased blood pressure in SHRs but not in WKY rats. 20 Additionally, augmented expression of iNOS is associated with hypertension. 21 These results indicate that the NOS system is involved in central cardiovascular regulation. Nevertheless, the relationship between elevated Ang II and reduced NO synthase activity and related modulation of cardiovascular function in the NTS has not been established.
In this study, we investigated whether inhibition of Ang II activity could induce depressor cardiovascular effects in the NTS. We determined which form of NOS could be activated by the addition of Ang II inhibitors. In addition, we investigated the downstream signaling pathway involved in Ang II effects in the NTS. Our results suggest that the extracellular signal-regulated kinase (ERK)1/2-ribosomal protein S6 kinase (RSK)-nNOS signaling pathway is involved in Ang IIand ROS-mediated modulation of blood pressure in the NTS.
Methods

Experimental Chemicals
All experimental drugs were purchased from Sigma-Aldrich (St Louis, Mo), except when otherwise noted.
Animals
Sixteen-week-old male SHRs were obtained from the National Science Council Animal Facility and housed in the animal room of Kaohsiung Veterans General Hospital (Kaohsiung, Taiwan). Humane treatment was administered at all times. The rats were kept in individual cages in a room where lighting was controlled (12 hours on/12 hours off), and the temperature was maintained between 23°C and 24°C. The rats were acclimatized to the housing conditions for 1 week and were then trained for 1 week to acclimate the animals to the procedure of indirect blood pressure measurement. The rats were randomly assigned to the 3 groups, with 6 rats per group: (1) SHR group, SHRs; (2) SHRϩlosartan group, SHRs fed with losartan (AT 1 R antagonist); (3) SHRϩtempol group, SHRs fed with tempol (superoxide dismutase mimetic). The SHRϩlosartan group was administered losartan (30 mg/kg per day) by gavage for 2 weeks. The SHRϩtempol group was given tempol (1 mmol/L), which was given in the drinking water for 2 weeks. The daily water consumption of the animals was measured. The rats were given normal rat chow (Purina, St Louis, Mo) and tap water ad libitum. All animal research protocols were approved by the Research Animal Facility Committee of Kaohsiung Veterans General Hospital.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results
Ang II Induces In Situ ROS Generation in the NTS
In this study, we used SHRs as our model because higher levels of Ang II and AT 1 R were reported in these animals as compared with WKY rats. 11, 22 Previous studies suggested that in vivo Ang II increases ROS generation via NAD(P)H oxidase in NTS neurons. 9 Therefore, we determined the in situ level of ROS in the NTS to establish an association between Ang II and ROS in SHRs. Figure 1A shows many cells in the NTS with high dihydroethidium fluorescence activity. Pretreatment with losartan (AT 1 R antagonist) or tempol (superoxide dismutase mimetic) significantly decreased the dihydroethidium activity ( Figure 1B 
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Role of Ang II in Mediating the Effect of the NTS on Blood Pressure in SHRs
To assess whether Ang II and ROS participate in the blood pressure modulatory effects of the NTS of SHRs, we investigated the inhibitory effects of losartan or tempol, on blood pressure effects in the peripheral nervous system and NTS. Figure 2A shows the time-course measurements of systolic blood pressure (SBP) from day 0 to day 28. Administration of losartan or tempol began at day 0. At day 4 after losartan or tempol treatment, the SBP decreased significantly ( Figure  2A ; 188Ϯ5 versus 155Ϯ6 and 165Ϯ5 mm Hg, PϽ0.05, nϭ6). The maximal decrease in SBP was observed 14 days after losartan or tempol treatment (184Ϯ4 versus 146Ϯ3, and 149Ϯ3 mm Hg, PϽ0.05, nϭ6). At day 15, we administration of the medication was stopped and the rats began to recover from losartan or tempol treatment. At day 28, 14 days after recovery from losartan or tempol treatment, the SBP of the treated rats had risen to the same level as observed in control rats. Interestingly, NO production in the NTS was found to have increased significantly after treatment with losartan or tempol for 14 days ( Figure 2B , blank bars; 0.15Ϯ0.05 versus 1.11Ϯ0.13 and 0.67Ϯ0.04 mol/L per microgram of protein, PϽ0.05, nϭ6). After recovery from losartan or tempol treatment, no differences were seen in NO production between the control and experimental groups ( Figure 2B , hatched bars; 0.13Ϯ0.01 versus 0.14Ϯ0.02 and 0.14Ϯ0.01 mol/L per microgram of protein, PϾ0.05, nϭ6).
Ang II Attenuates nNOS Phosphorylation in the NTS
We further investigated whether eNOS, iNOS, or nNOS contributes to the blood pressure modulatory effects of Ang II in the NTS of SHRs. Immunoblotting analyses of proteins extracted from the NTS demonstrated that systemic treatment with losartan or tempol did not increase eNOS S1177 phosphorylation (Online Figure I Figure 3D and 3E shows that losartan or tempol treatment significantly increased the numbers of phosphorylated (P)-nNOS S1416 -positive cells in the NTS, as compared with SHR control rats (14Ϯ3 versus 32Ϯ5 and 35Ϯ4, PϽ0.05, nϭ6). After recovery from losartan or tempol treatment, there were no differences in nNOS S1416 phosphorylation levels between control and experimental groups (Online Figure II 
RSK Binds and Phosphorylates nNOS at Ser1416
To determine which kinase might be responsible for nNOS S1416 phosphorylation, we used 2 bioinformatic resources (the Net-PhosK 1.0 Server [http://www.cbs.dtu.dk/services/NetPhosK] and the Kinase Phos 2.0 [http://kinasephos2.mbc.nctu.edu.tw]), to predict interrelated proteins. The results suggested that RSK could phosphorylate nNOS S1416 with a score of 0.53. We then performed coimmunoprecipitation assays to analyze whether RSK bound to nNOS. The NTS lysate was immunoprecipitated with anti-nNOS or anti-P-RSK T359/S363 antibody and was then probed with T-nNOS and P-RSK T359/S363 antibodies. The results showed P-RSK T359/S363 coimmunoprecipitated with nNOS (Figure 4A, lanes 2 and 3). An in vitro kinase assay was then performed to determine whether RSK directly phosphorylated nNOS S1416 in vitro. We incubated purified nNOS protein with RSK immunoprecipitated from NTS lysate, in the presence of ATP, for the reaction time indicated. Figure 4B and 4C shows the time-dependent increase in Ser1416 phosphorylation of nNOS by RSK ( Figure 4B and 4C; from 0 to 2 hours; 1.0Ϯ0.1 versus 2.1Ϯ0.1, and 2.5Ϯ0.2-fold, PϽ0.05, nϭ6).
RSK Is Regulated by ERK1/2 to Modulate nNOS Activity in the NTS
RSK has previously been shown to be phosphorylated by ERK1/2 to activate the downstream signaling cascade. 23, 24 To determine whether RSK and ERK1/2 were activated by treatment with losartan or tempol, we performed immunoblotting analyses with antibodies specific for P-RSK T359/S363 and P-ERK1/2 T202/Y204 to examine the phosphorylation levels of RSK and ERK1/2. Figure 5A and 5B shows that, after systemic treatment with losartan or tempol, the phosphorylation levels of RSK in the NTS were increased significantly in comparison with the SHR control (1.00Ϯ0.18 versus 1.57Ϯ0.06, 1.44Ϯ0.12-fold, PϽ0.05, nϭ6). ERK1/2 phosphorylation was also significantly increased in comparison with SHR control ( Figure 5A and 5B; 1.00Ϯ0.33 versus 3.90Ϯ0.77, and 3.42Ϯ0.33-fold, for ERK1 and 1.00Ϯ0.21 versus 2.51Ϯ0.27, and 2.30Ϯ0.29-fold, for ERK2, PϽ0.05, nϭ6). After recovery from losartan or tempol treatment, there were no differences in RSK and ERK1/2 phosphorylation levels between in the control and experimental groups (Online Figure III, A and B; PϾ0.05, nϭ6 ).
Central Administration of Losartan or Tempol Activates ERK1/2-RSK-nNOS Pathway
To explore whether central administration of losartan or tempol also upregulated ERK1/2, RSK, and nNOS activity, we performed bilateral microinjections of losartan (6 pmol/60 nL) or tempol (50 nmol/60 nL) or vehicle into the NTS of SHRs. Online Figure V , A and B, shows that, after microinjection of losartan or tempol, the phosphorylation levels of ERK1/2 and RSK in the NTS were significantly increased compared with SHR controls (1.00Ϯ0.39 versus 4.57Ϯ0.34-and 4.05Ϯ0.53-fold for ERK1; 1.00Ϯ0.59 versus 3.45Ϯ0.70-and 3.59Ϯ0.41-fold for ERK2; 1.00Ϯ0.32 versus 3.03Ϯ0.29-and 2.45Ϯ0.57-fold for RSK, PϽ0.05, nϭ6). nNOS S1416 phosphorylation was significantly increased compared with SHR controls (Online Figure V, C and D; 1.00Ϯ0.21 versus 2.56Ϯ0.17, and 2.41Ϯ0.18-fold, for nNOS, PϽ0.05, nϭ6).
Mitogen-Activated Protein Kinase-ERK Kinase Inhibitor Attenuated Losartan-or Tempol-Induced ERK1/2-RSK-nNOS Pathway Activity in the NTS
To test whether the mitogen-activated protein kinase-ERK kinase 1/2 (MEK-ERK1/2)-RSK cascade might reduce losartan-or tempol-induced nNOS phosphorylation, we investigated the effect of the MEK inhibitor, PD98059 on ERK1/2, RSK and nNOS phosphorylation in the NTS. Immunoblotting analyses showed that pretreatment with PD98059 attenuated losartan-or tempol-induced ERK1/2 T202/Y204 and RSK T359/S363 phosphorylation in the NTS (Online Figure VI, A and B; 1 .00Ϯ0.19-versus 1.22Ϯ0.11-and 1.11Ϯ0.07-fold for ERK1; 1.00Ϯ0.11-versus 1.02Ϯ0.11-and 0.99Ϯ0.18-fold for ERK2; 1.00Ϯ0.32-versus 0.99Ϯ0.29and 1.28Ϯ0.57-fold for RSK, PϾ0.05, nϭ6;). nNOS S1416 phosphorylation levels were also reduced by PD98059 treatment (Online Figure VI, C and D; 1.00Ϯ0.22 versus 1.23Ϯ0.11, and 1.13Ϯ0.10-fold, for nNOS, PϾ0.05, nϭ6).
Discussion
In the present study, our data revealed that Ang II induces ROS production ( Figure 1 ) to impair NO production in the NTS Figure 3 . Quantitative immunoblotting and immunohistochemical analysis of nNOS S1416 phosphorylation in the NTS following treatment with losartan or tempol. A, Diagrammatic representation of the rat NTS. B, Immunoblot depicting low levels of P-nNOS S1416 protein in the NTS of SHRs (lane 1). Losartan or tempol treatment increased the level of P-nNOS S1416 protein (lanes 2 and 3) . C, Densitometric analysis of P-nNOS S1416 levels before and after treatment with losartan or tempol. Bar values are shown as meansϮSEM (nϭ6). *PϽ0.05 vs lane 1 and #PϽ0.05 vs lane 1. D, In situ qualitative analysis by immunohistochemical staining of P-nNOS S1416 -positive cells after treatment with losartan or tempol. The arrowhead indicates the central canal. Arrows indicate the P-nNOS S1416 -positive cells. The scale bar represents 200 m. Note the increased numbers of P-nNOS S1416 -positive cells after losartan or tempol treatment, as compared with SHR controls. E, Graphs depicting quantitative analysis of in situ P-nNOS S1416 -expressing cells in the NTS of SHRs after systemic treatment with losartan or tempol. The percentage of P-nNOS S1416 -positive cells was determined by counting P-nNOS S1416expressing cells in each hemisphere of the NTS at ϫ200 magnification. These counts were divided by all the cells in the same paraffin section. The statistical analysis was performed with a paired Student t test. *PϽ0.01 and #PϽ0.01 (nϭ6). Note the significant increase in P-nNOS S1416 -positive cells after treatment with losartan or tempol.
( Figure 2B ). ROS in the brain are thought to contribute to the neuropathogenesis of hypertension by enhancing sympathetic nervous system activity. 12 The essential NAD(P)H oxidase subunit gp91 phox is present in somatodendritic and axonal profiles that contain AT 1 R in the NTS. NAD(P)H oxidase subunits are also present in neurons and astroglia in the medial NTS. 25 In vivo, Ang II also increases ROS generation via NAD(P)H oxidase in NTS neurons. 9 When compared with WKY rats, SHRs exhibit increased ROS production not only in the aorta, but also in the NTS. 26, 27 Tempol (4-hydroxy-2,2,6,6tetramethyl piperidinoxyl) can permeate biological membranes to scavenge superoxide anions. 28 Tempol is not an antihypertensive drug; however, in our study, it demonstrated an antihypertensive effect. Our present study provides further support for these observations by showing the in situ expression of ROS in the NTS of SHRs. The inhibition of the AT 1 R by losartan and the inhibition of superoxide production by tempol decreased ROS production in the NTS of SHRs. These results also demonstrate that tempol inhibits Ang II-mediated superoxide production and hypertension, as Nishiyama et al described previously. 29 Our previous study showed that eNOS might play a critical role in NTS cardiovascular function via the adenosine-ERK1/2-eNOS signaling pathway. 2 Intra-NTS eNOS gene delivery was also found to induce a depressor response in SHRs. 19 Paton and colleagues demonstrated that eNOS-generated NO in the NTS plays a role in the control of baroreflex gain and arterial pressure. 30 Furthermore, previous reports showed that iNOS is involved in cardiovascular modulation in the brain stem. [31] [32] [33] In our present study, we did not detect reductions of eNOS or iNOS activity after inhibition of Ang II downstream of AT 1 R or depletion of ROS in the NTS of SHRs (Online Figure I) . However, we observed increased in nNOS S1416 phosphorylation levels in the NTS using immunoblotting and immunohistochemistry analysis (Figure 3 ). This evidence suggests that nNOS might be one of the downstream targets of Ang II that is involved in NO production and that modulates blood pressure function in the NTS of SHRs. We observed only slight differences between the losartan-treated group and the tempol-treated group, ROS production, blood pressure, NO production, and nNOS phosphorylation. These results indicate that a ROSdependent but AT 1 R-independent mechanism may exist. However, this mechanism remains unclear.
Interestingly, our results identified RSK as a key factor in the activation of nNOS ( Figure 4B ). RSK is located downstream of the Raf-MEK-ERK protein kinase cascade and contains 2 functional kinase domains: an N-terminal kinase that phosphorylates the substrates of RSK and a C-terminal kinase involved in the activation of RSK itself. 34 A previous study demonstrated that vascular nNOS expression is selectively increased in response to platelet-derived growth factor through MEK/ERK cascade activation. 35 In addition, epidermal growth factor stimulation was found to induce ERK1/2 activation to form RSK-nNOS complexes in the brain's neuronal cells. RSK may phosphorylate nNOS S847 to block the accumulation of toxic levels of NO. 36 In our study, we verified an interaction between RSK and nNOS through a coimmunoprecipitation assay. However, our results showed RSK directly increased nNOS phosphorylation at Ser1416 in a time-dependent manner in vitro ( Figure 4B and 4C) . The RSK-induced phosphorylation of Ser1416, a proposed activation site for nNOS, 37, 38 may result in the production of NO in the NTS ( Figure 2B ), which in turn could modulate cardiovascular effects. Thus, we propose that the ERK1/2-RSK-nNOS pathway may participate in central blood pressure regulation by Ang II in SHRs.
We used systemic administration of losartan or tempol to block Ang II-induced ERK1/2-RSK-nNOS pathway downregulation. We corroborated these results by using central administration of losartan or tempol to block Ang II-induced ERK1/2-RSK-nNOS signaling. Because systemic inhibition of AT 1 R could induce nonneuronal AT 1 R-mediated events through multiple signaling pathways, many unknown factors might regulate blood pressure and protein expression in this context. In our experiments, microinjection of losartan or tempol into the NTS induced ERK1/2 T202/Y204 , RSK T359/S363 , and nNOS S1416 phosphorylation (Online Figure V) , and these phosphorylation events could be blocked by central administration of PD98059 after systemic administration of losartan or tempol (Online Figure  VI) . Taken together, these results indicate that an ERK1/2-RSK-nNOS mechanism may exist in the NTS (Figure 6 ).
In our present study, SHRs were used as an animal model to investigate the molecular signaling mechanism of Ang IIinduced hypertension in the NTS. High levels of Ang II in the SHRs allowed systemic administration of AT 1 R or ROS inhib-itors and monitoring of the regulation of blood pressure induced by these inhibitors. However, we found low Ang II levels in WKY rats, a normotensive genetic model of SHRs. Previously, Mallem et al demonstrated no significant difference in SBP between losartan-treated WKY and sham control WKY rats. 39 Sun et al also showed that losartan attenuated the increase of BP and ROS generation after administration of Ang II in WKY rats. 14 These studies suggest that Ang II might also participate in a ROS-dependent pathway to modulate blood pressure in normotensive WKY rats. However, Qadri et al revealed that there are basic differences between the role of nNOS in SHRs and WKY rats. 20 We also observed no significant changes in SBP or ERK1/2, RSK, or nNOS activations after systemic administration of losartan or tempol in WKY rats, as compared to control (Online Figure IV) . Thus, further studies are needed to validate this proposed signaling mechanism in the NTS of WKY rats. Intracellular ROS is increased by ligand-induced receptor activation, and accumulating evidence suggests that these endogenously derived ROS may play important roles as signaling molecules. 40 ERK1/2 is involved in cellular differentiation, proliferation and development in neuronal cells. Wu et al demonstrated that ROS can enhance protein tyrosine kinase activity to regulate ERK1/2 phosphorylation in neuroblastoma in vitro. 41 Chen et al also reported that activation of protein phosphatases (eg, PP2A or PP5) can inhibit hydrogen peroxide-induced ERK1/2 phosphorylation in neuronal cells. 42 However, in our study, we showed that ROS accumulation inhibited ERK1/2 activation in the NTS and induced hypertension. ERK1/2 not only regulates neuronal development but also Figure 6 . The proposed Ang II-induced signaling pathway in the regulation of blood pressure in the NTS of SHRs. Ang II binds to the AT 1 R, leading to superoxide production. Superoxide accumulation may inhibit ERK1/2 activity. Moreover, RSK and nNOS cascade activity is also inhibited. This ultimately leads to decreased NO concentrations in the NTS and increased blood pressure. Ang II may inhibit ERK1/2-RSK-nNOS signaling, not only through ROS but also through other signaling molecules, to modulate blood pressure in the NTS of SHRs. However, NO may also combine with superoxide (O 2 Ϫ ) to form peroxynitrite (ONOO Ϫ ) to reduce its bioavailability.
play regulatory roles in neurons in response to various physiological stimuli. The possible mechanism connecting ROS and ERK1/2 in the NTS remain to be elucidated.
In conclusion, we present a novel ERK1/2-RSK-nNOS signaling pathway in the NTS that allows us to dissect the Ang II signaling pathway regarding the inhibition of NO production in the regulation of blood pressure. Our results suggest a possible interaction between RSK and nNOS S1416 in the NTS. The present data further demonstrate that Ang II may modulate central blood pressure effects via ROS to downregulate ERK1/2, RSK and nNOS.
